RxDoctor Payments Data

Julia Christopher, DO

Pulmonary Disease · Reno, NVNPI 1447601281

Payments from drug & device makers

What this record shows

This record is dominated by education: $5,517 of the $8,303 with a category attached, or 66.4%. Intuitive Surgical accounts for 83.7% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $7,189, more than ten times the $40 reported in 2019.

$8,303in general payments, 2019–2025

Across 39 payments — averaging $212.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Inari Medical, Inc.$335
  • Baxter Healthcare$299
  • AstraZeneca$215
  • GSK$159
  • Regeneron Healthcare Solutions, Inc.$103
  • plus $246 from 6 others

What the payments were for

  • Travel & lodging$1,02512%
  • Food & beverage$1,76121%
  • Education$5,51766%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,303 in reported general payments places this provider in the 75th percentile of 84 pulmonary disease providers in Nevada.

See all pulmonary disease providers in Nevada

Medicare billing

Part B allowed, 2024
$60,263
Medicare patients
358
Services billed
752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$45,681
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$12,179
Advair HfaFluticasone Propion/Salmeterol16$7,067
Wixela InhubFluticasone Propion/Salmeterol13$2,177
Albuterol Sulfate HfaAlbuterol Sulfate39$800
Azithromycin17$348
Montelukast Sodium19$194
Prednisone18$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$159$45,68157 claims
AstraZenecaBreztri Aerosphere$215$12,17913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 84 pulmonary disease providers in Nevada.

Other pulmonary disease in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →